A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD
Latest Information Update: 09 Jul 2024
At a glance
- Drugs Vorolanib (Primary) ; Aflibercept
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms DAVIO 2
- Sponsors EyePoint Pharmaceuticals
- 26 Jun 2024 According to an EyePoint Pharmaceuticals media release, company has hosted an R&D Day on Wednesday, June 26, 2024 from 8:00 a.m. to 9:30 a.m. ET to discuss review of Phase 2 DAVIO 2 trial results in wet AMD, including 12-month topline data.
- 18 Jun 2024 According to an EyePoint Pharmaceuticals media release, company will host an R&D Day on Wednesday, June 26, 2024 from 8:00 a.m. to 9:30 a.m. ET to discuss review of Phase 2 DAVIO 2 trial results in wet AMD, including 12-month topline data.
- 08 May 2024 According to an EyePoint Pharmaceuticals media release, an encore presentation of the DAVIO 2 clinical trial results will be presented at the Retina World Congress 2024.